

PRODUCT INFORMATION



GSK199 (hydrochloride)

Item No. 17489

Formal Name: [(3R)-3-amino-1-piperidinyl]
[2-(1-ethyl-1H-pyrrolo[2,3-b]
pyridin-2-yl)-7-methoxy-1-
methyl-1H-benzimidazol-5-yl]-
methanone, monohydrochloride

MF: C₂₄H₂₈N₆O₂ • HCl


FW: 469.0

Purity: ≥98%

Stability: ≥2 years at -20°C

Supplied as: A crystalline solid

UV/Vis.: λ_{max}: 219, 244, 309 nm



Laboratory Procedures

For long term storage, we suggest that GSK199 (hydrochloride) be stored as supplied at -20°C. It should be stable for at least two years.

GSK199 (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the GSK199 (hydrochloride) in the solvent of choice. GSK199 (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of GSK199 (hydrochloride) in these solvents is approximately 30 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of GSK199 (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of GSK199 (hydrochloride) in PBS, pH 7.2, is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Protein arginine deiminase 4 (PAD4) mediates the transformation of protein arginine into citrulline. Citrullination of proteins has normal roles in gene regulation and pathological roles in immunological and inflammatory diseases.¹ GSK199 is a reversible inhibitor of PAD4 (IC₅₀ = 200 nM) that binds to the low-calcium form of the enzyme and is selective for PAD4 over PAD1-3.² It is less potent than the related PAD4 inhibitor GSK484 (Item No. 17488), which demonstrates an IC₅₀ value of 50 nM.² GSK199 can inhibit the citrullination of PAD4 target proteins and diminish the formation of neutrophil extracellular traps in mouse neutrophils.²

References

1. Jones, J.E., Causey, C.P., Knuckley, B., *et al.* Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential. *Curr. Opin. Drug Discov. Devel.* **12**(5), 616-627 (2009).
2. Lewis, H.D., Liddle, J., Coote, J.E., *et al.* Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. *Nat. Chem. Biol.* **11**(3), 189-191 (2015).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/15/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM